Prostate Cancer

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Reginald Tucker-Seeley, MA, ScM, ScD, concludes the program with advice for caregivers and patients with prostate cancer to maximize the benefit of treatment.

Alicia Morgans, MD, MPH, offers advice to patients newly diagnosed with prostate cancer and reviews educational resources available for patients and their caregivers.

Practical advice for improving clinical trials to ensure they are more reflective of the overall population of patients with prostate cancer.

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.

Rashid K. Sayyid, MD, MSc, gives a brief overview of treatment options for nonmetastatic castrate-resistant prostate cancer.

Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.

An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer.

A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer.

Adding BXCL701 to Keytruda tended to improve overall survival outcomes for patients with small cell neuroendocrine prostate cancer, according to phase 2 study results.

As Len Goodman’s cause of death was announced and LSU defenseman Greg Brooks announces rare form of brain cancer, here is what’s happening in the oncology space this week.

A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.

Expert perspectives on how clinical trials and real-world evidence contribute to treatment decisions in prostate cancer.

I knew virtually nothing about cancer until I became a caregiver for my aunt Carolyn, who died of colorectal cancer in 2000.

A genitourinary oncologist provides insights on the treatment decision-making process and the roles of guidelines for prostate cancer.

An experienced public health and cancer researcher offers advice to patients newly diagnosed with prostate cancer and discusses barriers to access to care.

Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.

Reginald Tucker-Seeley, MA, ScM, ScD, gives an overview of the screening and diagnosis process of prostate cancer.

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed.

In honor of Prostate Cancer Awareness Month, we looked back at some of our most viewed and significant prostate cancer content from the summer of 2023.